Searched for
NOVO NORDISK DISPUTE
Hims earnings today: Why Hims & Hers Health stock dropped despite raising revenue forecast - here's what investors need to knowHims stock after Hims & Hers earnings: Hims & Hers Health shares dropped significantly after reporting a surprise first-quarter loss and re...- US stock market on the verge of largest loss today: Dow, S&P 500, Nasdaq 100 wiped out over 1.5% as losses accelerate; Magnificent Seven stocks take Trump tariff toll — check the biggest losers hereUS stock market plunge deepened today as the Dow Jones crashed 814 points, down 1.64%. The S&P 500 fell 1.23%. The Nasdaq dropped 1.44%. Tr...
- Sun Pharma gets DCGI nod for Wegovy-like weight loss drug, launch after Novo Nordisk's patent expirySun Pharma has received DCGI approval to launch Noveltreat, a generic semaglutide injection for chronic weight management in India. This GL...
- HC seeks Novo Nordisk's reply on Natco plea to revoke patentThe Delhi High Court has asked Novo Nordisk to explain why its patent for the diabetes and weight loss drug semaglutide should not be cance...
- Delhi HC refuses to stay order allowing Dr Reddy's to export semaglutideThe Delhi High Court has taken a firm stand by rejecting Novo Nordisk's plea to pause a prior ruling. This decision empowers Dr Reddy's Lab...
- Delhi HC allows Dr. Reddy’s to export weight-loss drug semaglutide, calls Novo Nordisk’s case ‘weak’The Delhi High Court declined to stay a single-judge order allowing Dr. Reddy's to export its semaglutide, observing Novo Nordisk's appeal ...
- Sun Pharma’s US innovative drug sales surpass generics for the first timeSun Pharma's U.S. innovative medicine sales have surpassed generics for the first time, driven by key products like Ilumya and Cequa. The l...
- Novo Nordisk's top investor seizes board controlIn a bold push for greater influence, a key investor in Novo Nordisk is advocating for a complete overhaul of the board. This strategic man...
- PhonePe files IPO papers; Tata 1mg funding frenzyPhonePe has confidentially filed its draft IPO papers with Sebi. This and more in today's ETtech Top 5.
- Natco Pharma sues Novo Nordisk in generic drug pushThe lawyers representing Natco Pharma informed the court that over the past few months it had approached Novo Nordisk to communicate on its...
- Is Novo Nordisk facing its “Nokia moment”? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forcesNovo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...
- US stock market today dances near record heights: S&P 500 flirts with all-time high, Nasdaq soars on tech euphoria, Dow holds steady as Fed decision loomsUS stock market today trends analysis shows Wall Street moving with cautious optimism as the S&P 500 flirts with record highs and tech stoc...
- Delhi HC seeks Dr Reddy's reply in Novo patent disputeThe Delhi High Court has directed Dr. Reddy's Labs to respond to Novo Nordisk's injunction petition concerning its weight-loss drug, semagl...
- Zydus Life's plans for cancer biosimilar hit a legal hurdleThe Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a patent infrin...
- Donald Trump selects anti-vaccine activist Robert F Kennedy Jr to lead top US health agencyDonald Trump appointed Robert F. Kennedy Jr. as head of the Department of Health and Human Services. Kennedy, an environmental activist, pl...
- Dr Reddy's gears up for weight loss drug studyDr Reddy's Laboratories has received approval from India's drug regulatory authority to conduct a bioequivalence study for the weight loss ...
- MNC pharma lobby pushes for single drug authority hereThe OPPI, which represents 22 pharma companies, including Abbott, Pfizer, Novartis, Novo Nordisk and Sanofi, also wants specialised patent ...
- Torrent Pharma: Trading at a significant discount; a good betThe pharma major is trading at a significant discount to its peers and presents a good entry point.
Load More
